Efficacy of extended thrombo-prophylaxis in major abdominal surgery: What does the evidence show?

Summary

Venous thromboembolism (VTE) is a frequent complication following major abdominal surgery. The use of low-molecular-weight heparins (LMWH) to prevent thrombotic events in these patients is a common and well documented practice. However, there is some controversy surrounding the duration of the prophylaxis, as it has been suggested that the risk persists for several weeks after surgery.The objective of this meta-analysis is to systematically review the clinical studies that compared safety and efficacy of extended use of LMWH (for three to four weeks after surgery) versus conventional in-hospital prophylaxis. An electronic data base search was performed. Only randomized, controlled studies were eligible. Data on the incidence of deep vein thrombosis (DVT), VTE and bleeding were extracted. Only three studies fulfilled the inclusion criteria. The indication for surgery was neoplastic disease in 70.6% (780/1104) of patients. The administration of extended LMWH prophylaxis significantly reduced the incidence of VTE, 5.93% (23/388) versus 13.6% (55/405), RR 0.44 (CI 95% 0.28 – 0.7); DVT 5.93% (23/388) versus 12.9% (52/402), RR 0.46 (CI 95% 0,29 – 0,74); proximal DVT 1% (4/388) versus 4.72% (19/402), RR 0.24 (CI 95% 0.09 – 0,67). We found no significant difference in major or minor bleeding between the two groups: 3.85% (21/545) in the extended thrombo-prophylaxis (ETP) group versus 3.48% (19/559) in the conventional prophylaxis group; RR 1.12 (CI 95% 0.61 – 2.06). There was no heterogeneity between the studies. We conclude that ETP with LMWH should be considered as a safe and useful strategy to prevent VTE in high-risk major abdominal surgery.

Keywords

Cancer - major abdominal surgery - venous thromboembolism - low-molecular-weight heparins - extended thrombo-prophylaxis

• References

• 1 Geerts WH, Pineo GF, Heit JA. et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (Suppl. 03) 338S-400S.
• 2 Iversen LH, Thorlasius-Ussing O. Relations of coagulation test abnormalities to tumor burden and postoperative DVT in resected colorectal cancer. Thromb Haemost 2002; 87: 402-408.
• 3 Kakkar A, Haas S, Walsh D. et al. Prevention of peri-operative venous thromboembolism: outcome after cancer and non-cancer surgery. Thromb Haemost. 2001 XVIII Congress of ISTH Paris, A OC1732.
• 4 Seddighzadeh A, Shetty R, Goldhaber S. Venous thromboembolism in patients with active cancer. Thromb Haemost 2007; 98: 656-661.
• 5 Galster H, Kolb G, Kohsytorz A. et al. The pre-, peri-, and postsurgical activation of coagulation and the thromboembolic risk for different risk groups. Thromb Res 2000; 100: 381-388.
• 6 Rasmussen M. Preventing thromboembolic complications in cancer patients after surgery: a role for prolonged thromboprophylaxis. Cancer Treat Rev 2002; 28: 141-144.
• 7 Bergqvist D, Burmark US, Flordal PA. et al. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 XaI units in 2070 patients. Br J Surg 1995; 82: 496-501.
• 8 Scurr JH, Colerigde-Smith PD, Hasty JH.. Deep venous thrombosis: a continuing problem. Br Med J 1988; 297: 28.
• 9 Sørensen C, Andersen M, Kristiansen VB. et al. The occurrence of late thromboembolic complications after elective abdominal surgery. Ugskr laeg 1990; 152: 1586-1587.
• 10 Clarke-Pearson DL, Synan IS, Hinshaw WM. et al. Prevention of postoperative venous thromboembolism by external pneumatic calf compression in patients with gynecologic malignancy. Obstet Gynecol 1984; 63: 92-98.
• 11 Agnelli G, Bolis G, Capussotti L. et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg 2006; 243: 89-95.
• 12 Kakkar A, Haas S, Wolf H. et al. Evaluation of perioperative fatal pulmonary embolism and death in cancer surgical patients. Thromb Haemost 2005; 94: 867-871.
• 13 Mantel H, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-748.
• 14 Bergqvist D, Solhaug JH, Holmdahl L. et al. Pharmacokinetics, preliminary efficacy and safety of subcutaneous melagatran and oral ximelagatran: a multicenter study of thromboprophylaxis in elective abdominal surgery. Clin Drug Invest 2004; 24: 124-136.
• 15 Rasmussen MS, Wille-Jørgensen P. . Prolonged outof-hospital low molecular weight heparin prophylaxis against deep venous thrombosis in patients undergoing major abdominal surgery: a systematic review. Blood 2003; 102: A 1168.
• 16 Rasmussen MS, Wille-Jørgensen P. Extended outof- hospital low molecular weight heparin prophylaxis against venous thromboembolism in patients after cancer operations: a meta-analysis. J Thromb Haemost 2001; 3 (Suppl. 01) P2213.
• 17 Rasmussen MS.. Does prolonged thromboprophylaxis improve outcome in patients undergoing surgery?. Cancer Treat Rev 2003; 29 (Suppl. 02) 15-17.
• 18 Rasmussen MS, Wille-Jørgensen P, Jorgensen L. et al. Prolonged thromboprophylaxis with low molecular weight heparin (Dalteparin) following major abdominal surgery for malignancy. Blood 2003; 102: A186.
• 19 Rasmussen MS, Wille-Jørgensen P, Jorgensen L. et al. Prolonged thromboprophylaxis with Dalteparin may improve survival in patients operated on for abdominal cancer. J Thromb Haemost 2005; 3 (Suppl. 01) P2187.
• 20 Jorgensen LN, Lausen I, Rasmussen MS. et al. Prolonged thromboprophylaxis with low molecular weight heparin (tinzaparin) following major general surgery primarily for cancer: an individual patient data metaanalysis. J Thromb Haemost 2003; 1 (Suppl. 01) P1870.
• 21 Rasmussen MS, Wille-Jørgensen P, Jorgensen L. et al. Prolonged thromboprophylaxis with low molecular weight heparin (Dalteparin) following major abdominal surgery prevents late VTE: the FAME study. Pathophysiol Haemost Thromb 2003; 33 (Suppl. 01) 77-104.
• 22 Rasmussen MS, Wille-Jørgensen P, Jorgensen L. et al on behalf of the FAME investigators. Prolonged prophylaxis with dalteparin to prevent late thromboem-bolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study. J Thromb Haemost 2006; 4: 2384-2390.
• 23 Bergqvist D, Agnelli G, Cohen AT. et al ENOXACAN II Investigators. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002; 346: 975-980.
• 24 Lausen I, Jensen R, Jorgensen LN. et al. Incidence and prevention of deep venous thrombosis occurring late after general surgery: randomised controlled study of prolonged thromboprophylaxis. Eur J Surg 1998; 164: 657-663.
• 25 Sugarbaker DJ, Jaklitsch MT, Bueno R. et al. Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. J Thorac Cardiovasc Surg 2004; 128: 138-146.
• 26 Mason DP, Quader MA, Blackstone EH. et al. Thromboembolism after pneumonectomy for malignancy: an independent marker of poor outcome. J Thorac Cardiovasc Surg 2006; 131: 711-718.
• 27 Ziomek S, Read RC, Tobler HG. et al. Thromboembolism in patients undergoing thoracotomy. Ann Thorac Surg 1993; 56: 223-226.
• 28 Jadad AR, Moore RA, Carroll D. et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996; 17: 1-12.
• 29 Haas S, Wolf H, Kakkar AK. et al. Prevention of fatal pulmonary embolism and mortality in surgical patients: a randomized double-blind comparison of LMWH with unfractionated heparin. Thromb Haemost 2005; 94: 814-819.
• 30 Eikelboom JW, Quinlan DJ, Douketis JD. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet 2001; 358: 9-15.
• 31 Ricotta S, Iorio A, Parise P. et al. Post discharge clinically overt venous thromboembolism in orthopaedic surgery patients with negative venography--an overview analysis. Thromb Haemost 1996; 76: 887-892.
• 32 CANBESURE STUDY (Cancer, Bemiparin and Surgery Evaluation, NCT00219973). Available at: http://clinicaltrials.gov/ct/show/NCT00219973?order=4 Accesed December 15, 2007.
• 33 Fondaparinux in preventing blood clots in patients undergoing surgery for gynecologic cancer (NCT00381888). Available at: http://www.clinical trials.gov/ct/show/NCT00381888?order=2 Accesed December 15, 2007.